Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1

Study start date: September 1, 2004

Inclusion Criteria: * Willing to be followed for the duration of the study * Willing to use acceptable methods of contraception * Good general health Exclusion Criteria: * Clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease * Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the ability of the volunteer to understand and cooperate with the study * Liver, renal, or hematologic disease * Alcohol or drug abuse within 12 months of study entry * History of severe allergic reaction or anaphylaxis * Emergency room visit or hospitalization for severe asthma within 6 months of study entry * HIV-1 infected * HCV infected * Hepatitis B surface antigen positive * Known immunodeficiency syndrome * Use of corticosteroids or immunosuppressive drugs within 30 days of study entry. Participants who have used topical or nasal corticosteroids are not excluded. * Live vaccine within 4 weeks of study entry * Killed vaccine within 2 weeks of study entry * Blood products within 6 months of study entry * Investigational drugs or vaccines within 60 days prior to study entry or while currently enrolled in this clinical trial * Previously received a licensed or experimental yellow fever or dengue vaccine * Surgical removal of spleen * History of dengue virus infection or other flavivirus infection * Other condition that, in the opinion of the investigator, would affect the participant's participation in the study * Pregnancy or breastfeeding * Plan to travel to an area where dengue infection is common